Modulation of amyloid β peptide1-42 cytotoxicity and aggregation in vitro by glucose and chondroitin sulfate

Current Alzheimer Research

Volumn 7, Issue 5, 2010, Pages 428-438

  Fernandez Busquets X ^a,b   Ponce, J ^c,d   Bravo, R ^a,b   Arimon, M ^a,b   Martianez T ^c   Gella, A ^c   Cladera, J ^e   Durany, N ^c  

^a INSTITUTE FOR BIOENGINEERING OF CATALONIA IBEC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITAT INTERNACIONAL DE CATALUNYA   (Spain)

^d FUNDACIÓ INSTITUT D INVESTIGACIÓ EN CIÈNCIES DE LA SALUT GERMANS TRIAS I PUJOL   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Advanced glycation endproducts; Alzheimer's disease; Amyloid peptide; Amyloid fibrils; Apoptosis; Carbohydrates; Glycosaminoglycans

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID; AMYLOID BETA PROTEIN[1-42]; CARBOHYDRATE; CARNOSINE; CHONDROITIN SULFATE; DERMATAN SULFATE; FRUCTOSE; GLUCOSE; GLYCOSAMINOGLYCAN; PROTEOGLYCAN; PYRIDOXAMINE; THIOFLAVINE;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; ATOMIC FORCE MICROSCOPY; CELL PROTECTION; CELL VIABILITY; CHEMICAL MODIFICATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; FLUORESCENCE; GLUCOSE BRAIN LEVEL; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR MECHANICS; NERVE CELL CULTURE; NERVE DEGENERATION; NEUROBLASTOMA CELL; NEUROTOXICITY; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN STRUCTURE; WESTERN BLOTTING;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; CELL DEATH; CELL LINE, TUMOR; CHONDROITIN SULFATES; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; PEPTIDE FRAGMENTS;

EID: 78549247817     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720510791383787     Document Type: Article

References (93)

1. Heese K, Akatsu H. Alzheimer's disease An interactive perspective. Curr Alzheimer Res 3: 109-121 (2006).
2. Durany N, Münch G, Michel T, Riederer P. Investigations on oxidative stress and therapeutical implications in dementia. Eur Arch Psychiatry Clin Neurosci 249 (Suppl 3): 68-73 (1999).
3. Mott RT, Hulette CM. Neuropathology of Alzheimer's disease. Neuroimaging Clin N Am 15: 755-765 (2005).
4. LaFerla FM, Oddo S. Alzheimer's disease: Aβ, tau and synaptic dysfunction. Trends Mol Med 11: 170-176 (2005).
5. Kar S, Slowikowski SP, Westaway D, Mount HT. Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer's disease. J Psychiatry Neurosci 29: 427-441 (2004).
6. Arimon M, Díez-Pérez I, Kogan MJ, Durany N, Giralt E, Sanz F, et al. Fine structure study of Aβ1-42 fibrillogenesis with atomic force microscopy. FASEB J 19: 1344-1346 (2005).
7. Harper JD, Lieber CM, Lansbury PT, Jr. Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-β protein. Chem Biol 4: 951-959 (1997).
8. Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, Teplow DB. Amyloid β-protein (Aβ) assembly: Aβ40 and Aβ42 oligomerize through distinct pathways. Proc Natl Acad Sci USA 100: 330-335 (2003).
9. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 368: 387-403 (2006).
10. Wiltfang J, Esselmann H, Cupers P, Neumann M, Kretzschmar H, Beyermann M, et al. Elevation of β-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. J Biol Chem 276: 42645-42657 (2001).
11. Chan SL, Furukawa K, Mattson MP. Presenilins and APP in neuritic and synaptic plasticity: implications for the pathogenesis of Alzheimer's disease. Neuromol Med 2: 167-196 (2002).
12. Meredith SC. Protein denaturation and aggregation: cellular responses to denatured and aggregated proteins. Ann NY Acad Sci 1066: 181-221 (2005).
13. Catalano SM, Dodson EC, Henze DA, Joyce JG, Krafft GA, Kinney GG. The role of amyloid-beta derived diffusible ligands (ADDLs) in Alzheimer's disease. Curr Top Med Chem 6: 597-608 (2006).
14. Walsh DM, Selkoe DJ. Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein Pept Lett 11: 213-228 (2004).
15. Alexandrescu AT. Amyloid accomplices and enforcers. Protein Sci 14: 1-12 (2005).
16. 13C NMR spectroscopy. Proc Natl Acad Sci USA 89: 1109-1112 (1992).
17. Ruoslahti E. Brain extracellular matrix. Glycobiology 6: 489-492 (1996).
18. Ogata N, Takahashi I, Nakazawa K. Purification and characterization of chick corneal β-D-glucuronyltransferase involved in chondroitin sulfate biosynthesis. Biol Pharm Bull 25: 1282-1288 (2002).
19. Ancsin JB. Amyloidogenesis: historical and modern observations point to heparan sulfate proteoglycans as a major culprit. Amyloid 10: 67-79 (2003).
20. Hirschfield GM, Hawkins PN. Amyloidosis: new strategies for treatment. Int J Biochem Cell Biol 35: 1608-1613 (2003).
21. van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM, Verbeek MM. Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol 2: 482-492 (2003).
22. McLaurin J, Franklin T, Zhang X, Deng J, Fraser PE. Interactions of Alzheimer amyloid-β peptides with glycosaminoglycans. Effects on fibril nucleation and growth. Eur J Biochem 266: 1101-1110 (1999).
23. Yamaguchi I, Suda H, Tsuzuike N, Seto K, Seki M, Yamaguchi Y, et al. Glycosaminoglycan and proteoglycan inhibit the depolymerization of β2-microglobulin amyloid fibrils in vitro. Kidney Int 64: 1080-1088 (2003).
24. Gupta-Bansal R, Frederickson RC, Brunden KR. Proteoglycanmediated inhibition of Aβ proteolysis. A potential cause of senile plaque accumulation. J Biol Chem 270: 18666-18671 (1995).
25. Potter-Perigo S, Hull RL, Tsoi C, Braun KR, Andrikopoulos S, Teague J, et al. Proteoglycans synthesized and secreted by pancreatic islet β-cells bind amylin. Arch Biochem Biophys 413: 182-190 (2003).
26. Ancsin JB, Kisilevsky R. The heparin/heparan sulfate-binding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J Biol Chem 274: 7172-7181 (1999).
27. Cohlberg JA, Li J, Uversky VN, Fink AL. Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from α-synuclein in vitro. Biochemistry 41: 1502-1511 (2002).
28. Supattapone S. Prion protein conversion in vitro. J Mol Med 82: 348-356 (2004).
29. Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA. Assembly of microtubule-associated protein tau into Alzheimer-like filaments induced by sulphated glycosaminoglycans. Nature 383: 550-553 (1996).
30. Castillo GM, Lukito W, Wight TN, Snow AD. The sulfate moieties of glycosaminoglycans are critical for the enhancement of β-amyloid protein fibril formation. J Neurochem 72: 1681-1687 (1999).
31. Bravo R, Arimon M, Valle-Delgado JJ, Garcia R, Durany N, Castel S, et al. Sulfated polysaccharides promote the assembly of amyloid β1-42 peptide into stable fibrils of reduced cytotoxicity. J Biol Chem 283: 32471-32483 (2008).
32. Díaz-Nido J, Wandosell F, Avila J. Glycosaminoglycans and β-amyloid, prion and tau peptides in neurodegenerative diseases. Peptides 23: 1323-1332 (2002).
33. McLaurin J, Fraser PE. Effect of amino-acid substitutions on Alzheimer's amyloid-β peptide-glycosaminoglycan interactions. Eur J Biochem 267: 6353-6361 (2000).
34. DeGroot J. The AGE of the matrix: chemistry, consequence and cure. Curr Opin Pharmacol 4: 301-305 (2004).
35. Ahmed N. Advanced glycation endproducts role in pathology of diabetic complications. Diabetes Res Clin Pract 67: 3-21 (2005).
36. Dukic-Stefanovic S, Schinzel R, Riederer P, Münch G. AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs? Biogerontology 2: 19-34 (2001).
37. Richter T, Münch G, Luth HJ, Arendt T, Kientsch-Engel R, Stahl P, et al. Immunochemical crossreactivity of antibodies specific for advanced glycation endproducts with advanced lipoxidation endproducts. Neurobiol Aging 26: 465-474 (2005).
38. Wells-Knecht KJ, Zyzak DV, Litchfield JE, Thorpe SR, Baynes JW. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 34: 3702-3709 (1995).
39. Gasic-Milenkovic J, Loske C, Münch G. Advanced glycation end products cause lipid peroxidation in the human neuronal cell line SH-SY5Y. J Alzheimer's Dis 5: 25-30 (2003).
40. Kuhla B, Loske C, Garcia de Arriba S, Schinzel R, Huber J, Münch G. Differential effects of Advanced glycation endproducts and β-amyloid peptide on glucose utilization and ATP levels in the neuronal cell line SH-SY5Y. J Neural Transm 111: 427-439 (2004).
41. Neumann A, Schinzel R, Palm D, Riederer P, Münch G. High molecular weight hyaluronic acid inhibits advanced glycation end product-induced NF-kappaB activation and cytokine expression. FEBS Lett 453: 283-287 (1999).
42. Lüth HJ, Ogunlade V, Kuhla B, Kientsch-Engel R, Stahl P, Webster J, et al. Ageand stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer's disease brains. Cereb Cortex 15: 211-220 (2005).
43. Ko LW, Ko EC, Nacharaju P, Liu WK, Chang E, Kenessey A, et al. An immunochemical study on tau glycation in paired helical filaments. Brain Res 830: 301-313 (1999).
44. Loske C, Gerdemann A, Schepl W, Wycislo M, Schinzel R, Palm D, et al. Transition metal-mediated glycoxidation accelerates cross linking of β-amyloid peptide. Eur J Biochem 267: 4171-4178 (2000).
45. Münch G, Mayer S, Michaelis J, Hipkiss AR, Riederer P, Müller R, et al. Influence of advanced glycation end-products and AGE inhibitors on nucleation-dependent polymerization of β-amyloid peptide. Biochim Biophys Acta 1360: 17-29 (1997).
46. Münch G, Deuther-Conrad W, Gasic-Milenkovic J. Glycoxidative stress creates a vicious cycle of neurodegeneration in Alzheimer's disease a target for neuroprotective treatment strategies? J Neural Transm Suppl 303-307 (2002).
47. Münch G, Schinzel R, Loske C, Wong A, Durany N, Li JJ, et al. Alzheimer's disease synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 105: 439-461 (1998).
48. Münch G, Thome J, Foley P, Schinzel R, Riederer P. Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res Brain Res Rev 23: 134-143 (1997).
49. Encinas M, Iglesias M, Liu Y, Wang H, Muhaisen A, Cena V, et al. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J Neuro chem 75: 991-1003 (2000).
50. Datki Z, Juhasz A, Galfi M, Soos K, Papp R, Zadori D, et al. Method for measuring neurotoxicity of aggregating polypeptides with the MTT assay on differentiated neuroblastoma cells. Brain Res Bull 62: 223-229 (2003).
51. Levine H, III. Thioflavine T interaction with synthetic Alzheimer's disease β-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 2: 404-410 (1993).
52. Krebs MR, Bromley EH, Donald AM. The binding of thioflavin-T to amyloid fibrils: localisation and implications. J Struct Biol 149: 30-37 (2005).
53. Barten DM, Guss VL, Corsa JA, Loo A, Hansel SB, Zheng M, et al. Dynamics of β-amyloid reductions in brain, cerebrospinal fluid, and plasma of β-amyloid precursor protein transgenic mice treated with a γ-secretase inhibitor. J Pharmacol Exp Ther 312: 635-643 (2005).
54. Kislinger T, Humeny A, Pischetsrieder M. Analysis of protein glycation products by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Curr Med Chem 11: 2185-2193 (2004).
55. Plant LD, Boyle JP, Smith IF, Peers C, Pearson HA. The production of amyloid β peptide is a critical requirement for the viability of central neurons. J Neurosci 23: 5531-5535 (2003).
56. Yankner BA. Mechanisms of neuronal degeneration in Alzheimer's disease. Neuron 16: 921-932 (1996).
57. Giordano T, Pan JB, Monteggia LM, Holzman TF, Snyder SW, Krafft G, et al. Similarities between β amyloid peptides 1-40 and 40-1: effects on aggregation, toxicity in vitro, and injection in young and aged rats. Exp Neurol 125: 175-182 (1994).
58. Lambert MP, Stevens G, Sabo S, Barber K, Wang G, Wade W, et al. Beta/A4-evoked degeneration of differentiated SH-SY5Y human neuroblastoma cells. J Neurosci Res 39: 377-385 (1994).
59. Frautschy SA, Yang F, Calderón L, Cole GM. Rodent models of Alzheimer's disease: rat Aβ infusion approaches to amyloid deposits. Neurobiol Aging 17: 311-321 (1996).
60. Butterfield DA. Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain. Free Radic Res 36: 1307-1313 (2002).
61. Behl C, Davis JB, Klier FG, Schubert D. Amyloid β peptide induces necrosis rather than apoptosis. Brain Res 645: 253-264 (1994).
62. Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J Neurosci 13: 1676-1687 (1993).
63. Lue LF, Walker DG, Rogers J. Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol Aging 22: 945-956 (2001).
64. Cacquevel M, Lebeurrier N, Cheenne S, Vivien D. Cytokines in neuroinflammation and Alzheimer's disease. Curr Drug Targets 5: 529-534 (2004).
65. Li YP, Bushnell AF, Lee CM, Perlmutter LS, Wong SK. β-amyloid induces apoptosis in human-derived neurotypic SH-SY5Y cells. Brain Res 738: 196-204 (1996).
66. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, et al. Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-β precursor protein and amyloidogenic Aβ peptide formation. Cell 97: 395-406 (1999).
67. Bhatia R, Lin H, Lal R. Fresh and globular amyloid β protein (1-42) induces rapid cellular degeneration: evidence for AβP channel mediated cellular toxicity. FASEB J 14: 1233-1243 (2000).
68. Forloni G, Chiesa R, Smiroldo S, Verga L, Salmona M, Tagliavini F, et al. Apoptosis mediated neurotoxicity induced by chronic application of beta amyloid fragment 25-35. Neuroreport 4: 523-526 (1993).
69. Oppermann UC, Salim S, Tjernberg LO, Terenius L, Jörnvall H. Binding of amyloid β-peptide to mitochondrial hydroxyacyl-CoA dehydrogenase (ERAB): regulation of an SDR enzyme activity with implications for apoptosis in Alzheimer's disease. FEBS Lett 451: 238-242 (1999).
70. Huang Y, Erdmann N, Peng H, Zhao Y, Zheng J. The role of TNF related apoptosis-inducing ligand in neurodegenerative diseases. Cell Mol Immunol 2: 113-122 (2005).
71. Loh KP, Huang SH, De Silva R, Tan BK, Zhu YZ. Oxidative stress: apoptosis in neuronal injury. Curr Alzheimer Res 3: 327-337 (2006).
72. Roher AE, Baudry J, Chaney MO, Kuo YM, Stine WB, Emmerling MR. Oligomerizaiton and fibril asssembly of the amyloid-β protein. Biochim Biophys Acta 1502: 31-43 (2000).
73. Serpell LC. Alzheimer's amyloid fibrils: structure and assembly. Biochim Biophys Acta 1502: 16-30 (2000).
74. Mattson MP, Tomaselli KJ, Rydel RE. Calcium-destabilizing and neurodegenerative effects of aggregated β-amyloid peptide are attenuated by basic FGF. Brain Res 621: 35-49 (1993).
75. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, Cotman CW, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 300: 486-489 (2003).
76. Hu J, Akama KT, Krafft GA, Chromy BA, Van Eldik LJ. Amyloid β peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Brain Res 785: 195-206 (1998).
77. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, et al. Self-assembly of Aβ1-42 into globular neurotoxins. Biochemistry 42: 12749-12760 (2003).
78. Stine WB, Jr, Dahlgren KN, Krafft GA, LaDu MJ. In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis. J Biol Chem 278: 11612-11622 (2003).
79. Roher AE, Chaney MO, Kuo YM, Webster SD, Stine WB, Haverkamp LJ, et al. Morphology and toxicity of Abeta-(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's disease. J Biol Chem 271: 20631-20635 (1996).
80. Dahlgren KN, Manelli AM, Stine WB, Jr, Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-β peptides differentially affect neuronal viability. J Biol Chem 277: 32046-32053 (2002).
81. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, et al. Elevation of plasma beta-amyloid level by glucose loading in Alzheimer mouse models. Biochem Biophys Res Commun 385: 193-197 (2009).
82. Vitek MP, Bhattacharya K, Glendening JM, Stopa E, Vlassara H, Bucala R, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci USA 91: 4766-4770 (1994).
83. Valente T, Gella A, Fernàndez-Busquets X, Unzeta M, Durany N. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus. Neurobiol Dis 37: 67-76 (2010).
84. Takeuchi M, Bucala R, Suzuki T, Ohkubo T, Yamazaki M, Koike T, et al. Neurotoxicity of advanced glycation end-products for cultured cortical neurons. J Neuropathol Exp Neurol 59: 1094-1105 (2000).
85. Pereira C, Moreira P, Seiça R, Santos MS, Oliveira CR. Susceptibility to β-amyloid-induced toxicity is decreased in Goto-Kakizaki diabetic rats: involvement of oxidative stress. Exp Neurol 161: 383-391 (2000).
86. Song X, Wu B, Takata T, Wang X, Oizumi XS, Akisaki T, et al. Neuroprotective effect of D-fructose-1,6-bisphosphate against beta amyloid induced neurotoxicity in rat hippocampal organotypic slice culture: involvement of PLC and MEK/ERK signaling pathways. Kobe J Med Sci 51: 73-83 (2005).
87. Kowall NW, McKee AC, Yankner BA, Beal MF. In vivo neurotoxicity of beta-amyloid [beta(1-40)] and the beta(25-35) fragment. Neurobiol Aging 13: 537-542 (1992).
88. DeWitt DA, Silver J, Canning DR, Perry G. Chondroitin sulfate proteoglycans are associated with the lesions of Alzheimer's disease. Exp Neurol 121: 149-152 (1993).
89. Woods AG, Cribbs DH, Whittemore ER, Cotman CW. Heparan sulfate and chondroitin sulfate glycosaminoglycan attenuate β-amyloid(25-35) induced neurodegeneration in cultured hippocampal neurons. Brain Res 697: 53-62 (1995).
90. Pollack SJ, Sadler II, Hawtin SR, Tailor VJ, Shearman MS. Sulfated glycosaminoglycans and dyes attenuate the neurotoxic effects of β-amyloid in rat PC12 cells. Neurosci Lett 184: 113-116 (1995).
91. Brückner G, Hausen D, Hartig W, Drlicek M, Arendt T, Brauer K. Cortical areas abundant in extracellular matrix chondroitin sulphate proteoglycans are less affected by cytoskeletal changes in Alzheimer's disease. Neuroscience 92: 791-805 (1999).
92. McLaurin J, Kierstead ME, Brown ME, Hawkes CA, Lambermon MH, Phinney AL, et al. Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 12: 801-808 (2006).
93. Townsend M, Cleary JP, Mehta T, Hofmeister J, Lesne S, O'Hare E, et al. Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-β oligomers. Ann Neurol 60: 668-676 (2006).